Cynata (ASX:CYP) receives ~AU$1.65 million R&D Tax Incentive Refund - Kalkine Media

Follow us on Google News:
 Cynata (ASX:CYP) receives ~AU$1.65 million R&D Tax Incentive Refund
Image source: © Gajus | Megapixl.com


  • Cynata Therapeutics Limited has been granted a AU$1,654,310 R&D Tax Incentive Refund for FY21/22.
  • The refund strengthens Cynata’s healthy balance sheet, which stood at around AU$18.3 million cash at the end of the September quarter.
  • Cynata plans to utilise the funds to advance its diverse and advanced cell therapy product pipeline.

In the latest announcement, clinical-stage biotechnology company Cynata Therapeutics (ASX: CYP) revealed that it has received an R&D Tax Incentive Refund of AU$1.65 million for the financial year 2021/2022. The grant further strengthens Cynata’s cash position which was AU$18.3 million at the end of the September quarter.

Cynata Therapeutics is an Australian clinical-stage stem cell and regenerative medicine firm engaged in the development of therapies based on its unique and proprietary therapeutic stem cell platform technology, Cymerus™.

Cymerus™ makes use of Nobel prize winning iPSC (induced pluripotent stem cells) technology to produce mesenchymal stem cells (MSCs) from single donor and a single donation, to enable highly consistent MSC product manufacture at commercial scale.

Utilising the proceeds

According to the company announcement, Cynata will direct the funds obtained from The Tax Incentive Refund to build further resources that can contribute towards advancing its diverse and innovative cell therapy product pipeline. The Company currently has ongoing clinical trials in osteoarthritis and diabetic foot ulcers, with plans to soon commence clinical trials in in acute graft-versus-host disease (aGvHD) and renal transplantation.

About R&D Tax Incentive

The R&D Tax Incentive is one of the vital Australian Government programs that plays a significant role in encouraging firms to undertake research and development works that are progressive for the country.

Under the program, a tax offset is offered to the companies for eligible activities, including Cynata’s efforts for developing its proprietary Cymerus™ therapeutic mesenchymal stem cell (MSC) products.

Shares of Cynata were trading at AU$0.330 apiece on Monday (05 December 2022).


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK